Pfizer, Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
However, seasoned pharmaceutical investors recognize the industry's cyclical nature. The industry's rhythm of drug development, regulatory hurdles, marketing pushes, and patent expirations means that ...
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...
Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 focusing on vepdegestrant (ARV-471), an orally active selective oestrogen ...
The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...
IsomAb has also entered into a strategic collaboration with Pfizer Ignite to support preclinical development and IND-enabling studies for ISM-001, the company stated.
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Guggenheim has raked in an estimated $172mn in fees from advising Pfizer on nearly $400bn of completed and attempted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback